Bruker has unveiled a standardized nuclear magnetic resonance (NMR) spectroscopy platform for its clinical and diagnostics partners to help in cost-effective, high-performance NMR clinical screening and IVD-by-NMR discovery, development and validation of novel NMR assays.
The new platform offers higher information content and spectral feature differentiation, reproducibility, high throughput and reduced cost per sample for better clinical screening and IVD-by-NMR.
Equipped with high sensitivity and information-rich output at 600MHz proton-NMR frequency, the machine incorporates advanced hardware, software, automation, spectral libraries and standard operating procedures (SOPs) for high-performance bio-fluid screening and assay validation.
Based on Bruker-validated SOPs, the new user-friendly standardized platform delivers barcode analysis, control by a LIMS system, the high-throughput, temperature-controlled autosampler SampleJet, remote access, and automatic analysis and customizable analytical results reporting.
Moreover, it also helps in the development of diagnostic tools for body fluids, or even biopsy samples, which can deal with various medical questions.
As part of its association with Imperial College London, the AVANCE-IVDr platform has already enabled analysis of over 100,000 samples per year at the UK's recently opened MRC-NIHR Phenome Centre, while enabling epidemiological studies, clinical research and diagnosis.
